Wednesday, December 21, 2016

Revolution Medicines Picks Up $25M For Cancer Efforts

Redwood City-based Revolution Medicines, a biopharmaceuticals firm aiming to treat cancer by attacking frontier oncology targets, proteins which drive the growth of cancer, has raised $25M in a Series A extension financing. The funding came from The Column Group, in addition to earlier funding from Third Rock Ventures. Column Group partner Larry Lasky joins the company's board with the funding. Mark A. Goldsmith is President and CEO of Revolution Medicines. More information »